Formulations of anti-pain agents and methods of using the same

• US 20050256182A1
• Filed: 05/11/2005
• Published: 11/17/2005
• Est. Priority Date: 05/11/2004
• Status: Abandoned Application

• Current Assignee: Becton, Dickinson & Co
• Original Assignee: Becton, Dickinson & Co
• Inventors: Pettis, Ronald J., Kaestner, Scott A., Sutter, Diane E.
• Application Number:
  US11/126,335
• Publication Number:
  US 20050256182A1
• Time in Patent Office: Days
• US Class Current: 514/419
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

The present invention relates to novel anti-pain formulations and methods of their delivery. Anti-pain agents delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods, including oral, intramuscular and subcutaneous delivery. The methods of the present invention provide benefits and improvements over conventional drug delivery methods including dose sparing, increased drug efficacy, reduced side effects.

Claims

1. A formulation for parenteral administration comprising a triptan compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, wherein the formulation contains no NaCl.

2. The formulation of claim 1, wherein the triptan compound is sumatriptan or sumatriptan succinate.

3. The formulation of claim 1, wherein the triptan compound is almotriptan malate, rizatriptan benzoate, zolmitriptan, or naratriptan hydrochloride.

4. The formulation of claim 1, wherein the excipient is sugar- or carbohydrate-based tonicity agent.

5. The formulation of claim 4, wherein the tonicity agent is mannitol.

6. The formulation of claim 4, wherein the tonicity agent is dextrose.

7. The formulation of claim 4, wherein the tonicity agent is sorbitol.

8. The formulation of claim 2, wherein the sumatriptan succinate is present at a concentration of from about 20 mg/ml to about 40 mg/ml.

9. The formulation of claim 8, wherein the sumatriptan succinate is present at a concentration of from about 20 mg/ml to about 30 mg/ml.

10. The formulation of claim 2, wherein the sumatriptan succinate is present at a concentration of about 24 mg/ml.

11. The formulation of claim 10, which comprises about 33.6 mg sumatriptan succinate, about 0.71 mg dibasic sodium phosphate anhydrous, and about 19.49 mg mannitol, and wherein the pH of the formulation is adjusted to about 5.5.

12. The formulation of claim 2, wherein the sumatriptan succinate is present at a concentration of about 30 mg/ml.

13. The formulation of claim 12, which comprises about 42.0 mg sumatriptan succinate, about 0.71 mg dibasic sodium phosphate anhydrous, and about 12.21 mg mannitol, and wherein the pH of the formulation is adjusted to about 5.5.

14. A method of treating, preventing, or managing pain comprising administering by injection into the skin of a patient in need of such treatment, prevention, or management a formulation comprising sumatriptan, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient, wherein the formulation contains no NaCl.

15. The method of claim 14, wherein the formulation is injected into the intradermal and/or junctional compartment of the skin.

16. The method of claim 14, wherein the pharmaceutically acceptable salt is sumatriptan succinate.

17. The method of claim 14, wherein the excipient is sugar- or carbohydrate-based tonicity agent.

18. The method of claim 17, wherein the tonicity agent is mannitol.

19. The method of claim 17, wherein the tonicity agent is dextrose.

20. The method of claim 17, wherein the tonicity agent is sorbitol.

21. The method of claim 16, wherein the sumatriptan succinate is present at a concentration of from about 20 mg/ml to about 40 mg/ml.

22. The method of claim 16, wherein the sumatriptan succinate is present at a concentration of from about 20 mg/ml to about 30 mg/ml.

23. The method of claim 16, wherein the sumatriptan succinate is present at a concentration of about 24 mg/ml.

24. The method of claim 23, which comprises about 33.6 mg sumatriptan succinate, about 0.71 mg dibasic sodium phosphate anhydrous, and about 19.49 mg mannitol, and wherein the pH of the formulation is adjusted to about 5.5.

25. The method of claim 16, wherein the sumatriptan succinate is present at a concentration of about 30 mg/ml.

26. The method of claim 25, which comprises about 42.0 mg sumatriptan succinate, about 0.71 mg dibasic sodium phosphate anhydrous, and about 12.21 mg mannitol, and wherein the pH of the formulation is adjusted to about 5.5.

27. The method of claim 14, wherein the pain is nociceptive pain, neuropathic pain, acute pain, chronic pain, osteoarthritis, rheumatoid arthritis or tendonitis, myofascial pain, visceral pain, headache pain, reflex neurovascular dystrophy, reflex dystrophy, sympathetically maintained pain syndrome, causalgia, Sudeck atrophy of bone, algoneurodystrophy, shoulder hand syndrome, post-traumatic dystrophy, autonomic dysfunction, cancer-related pain, phantom limb pain, fibromyalgia, chronic fatigue syndrome, post-operative pain, spinal cord injury pain, central post-stroke pain, radiculopathy, allodynia, pain from hyperthermic or hypothermic conditions, diabetic neuropathy, luetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, or painful neuropathy induced iatrogenically by vincristine, velcade or thalidomide.

28. The method of claim 27, wherein the headache pain is migraine headache pain.

29. The method of claim 14, wherein the administration is injection using a syringe.

30. The method of claim 29, wherein the injection is done by penetrating skin to a depth of about 0.5 mm to about 3 mm.

31. The method of claim 30, wherein the injection is done by penetrating skin to a depth of about 1 mm to about 3 mm.

32. The method of claim 30, wherein the injection is done by penetrating skin to a depth of about 2 mm to about 3 mm.

33. The method of claim 30, wherein the injection is done by penetrating skin to a depth of about 1.5 mm.

34. The method of claim 30, wherein the injection is done by penetrating skin to a depth of about 2 mm.

35. The method of claim 30, wherein the injection is done by penetrating skin to a depth of about 3 mm.

36. The method of claim 14, wherein sumatriptan, or a pharmaceutically acceptable salt thereof, is administered in combination with a second anti-pain agent.

37. The method of claim 36, wherein the second anti-pain agent is an antidepressant, an anticonvulsant, an antihypertensive, an anxiolytic, a calcium channel blocker, a muscle relaxant, an analgesic, an anti-inflammatory agent, a cox-2 inhibitor, an α

-adrenergic receptor antagonist, ketamine, an anesthetic, an immunomodulatory agent, an immunosuppressive agent, a corticosteroid, hyperbaric oxygen, or an NMDA antagonist.

38. The method of claim 36, wherein sumatriptan, or a pharmaceutically acceptable salt thereof, and the second anti-pain agent are simultaneously administered.

39. The method of claim 36, wherein sumatriptan, or a pharmaceutically acceptable salt thereof, and the second anti-pain agent are sequentially administered.